**Author details**

Caryl J. Antalis and Kimberly K. Buhman *Indiana University School of Medicine & Purdue University, USA* 

#### **5. References**


Brown, M. S. and J. L. Goldstein (1997). "The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor." *Cell* 89(3): 331-340.

640 Lipoproteins – Role in Health and Diseases

Caryl J. Antalis and Kimberly K. Buhman

*Cancer Res Treat* 122(3): 661-670.

*Metastasis* 28(8): 733-741.

*Cardiovasc Ther* 26(4): 297-316.

*Biol Ther* 9(12): 1025-1032.

*Cancer Res* 60(8): 2247-2252.

*Indiana University School of Medicine & Purdue University, USA* 

types of cancer.

**Author details** 

**5. References** 

49-61.

that can increase cholesterol efflux and HDL-C levels without stimulating lipid biosynthesis in the liver, needed to treat cardiovascular disease and metabolic syndrome, may also be useful in cancer (Ratni, Blum-Kaelin et al. 2009). Dietary regimens targeting fat and cholesterol reduction in those with hyperlipidemia, with known benefits in preventing and treating heart disease, may be recommended to decrease the risk or recurrence of some

Ahern, T. P., L. Pedersen, et al. (2011). "Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study." *J Natl Cancer Inst* 103(19): 1461-1468. Ahn, J., U. Lim, et al. (2009). "Prediagnostic total and high-density lipoprotein cholesterol

Antalis, C. J., T. Arnold, et al. (2010). "High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation." *Breast* 

Antalis, C. J., A. Uchida, et al. (2011). "Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification." *Clin Exp* 

Bahl, M., M. Ennis, et al. (2005). "Serum lipids and outcome of early-stage breast cancer:

Batetta, B., A. Pani, et al. (1999). "Correlation between cholesterol esterification, MDR1 gene expression and rate of cell proliferation in CEM and MOLT4 cell lines." *Cell Prolif* 32(1):

Beltowski, J. (2008). "Liver X receptors (LXR) as therapeutic targets in dyslipidemia."

Bemlih, S., M. D. Poirier, et al. (2010). "Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines." *Cancer* 

Bjorge, T., A. Lukanova, et al. (2011). "Metabolic risk factors and ovarian cancer in the

Blackburn, G. L. and K. A. Wang (2007). "Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS)." *Am J Clin Nutr* 86(3): s878-881. Boudjelal, M., Z. Wang, et al. (2000). "Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes."

Bozza, P. T. and J. P. Viola (2010). "Lipid droplets in inflammation and cancer."

Metabolic Syndrome and Cancer project." *Int J Epidemiol* 40(6): 1667-1677.

*Prostaglandins Leukot Essent Fatty Acids* 82(4-6): 243-250.

results of a prospective cohort study." *Breast Cancer Res Treat* 94(2): 135-144.

and risk of cancer." *Cancer Epidemiol Biomarkers Prev* 18(11): 2814-2821.


Joseph, S. B., A. Castrillo, et al. (2003). "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors." *Nat Med* 9(2): 213-219.

642 Lipoproteins – Role in Health and Diseases

124(1): 35-46.

Flick, E. D., L. A. Habel, et al. (2009). "Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study." *Drugs* 69(11): 1445-1457. Freed-Pastor, W. A., H. Mizuno, et al. (2012). "Mutant p53 disrupts mammary tissue

Freeman, M. R., B. Cinar, et al. (2007). "Transit of hormonal and EGF receptor-dependent

Freitas, I., P. Pontiggia, et al. (1990). "Histochemical probes for the detection of hypoxic

Gazzerro, P., M. C. Proto, et al. (2012). "Pharmacological actions of statins: a critical

Gebhard, R. L., R. V. Clayman, et al. (1987). "Abnormal cholesterol metabolism in renal clear

Goldstein, J. L., R. A. DeBose-Boyd, et al. (2006). "Protein sensors for membrane sterols." *Cell*

Gordan, J. D., C. B. Thompson, et al. (2007). "HIF and c-Myc: sibling rivals for control of

Guo, D., F. Reinitz, et al. (2011). "An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway." *Cancer Discov* 1(5): 442-456. Ha, M., J. Sung, et al. (2009). "Serum total cholesterol and the risk of breast cancer in

Hager, M. H., K. R. Solomon, et al. (2006). "The role of cholesterol in prostate cancer." *Curr* 

Hamilton, R. J., L. L. Banez, et al. (2010). "Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional

Hamilton, R. J., K. C. Goldberg, et al. (2008). "The influence of statin medications on

Hede, K. (2011). "Hints that statins reduce colon cancer risk finally being put to the test." *J* 

Hirakawa, T., K. Maruyama, et al. (1991). "Massive accumulation of neutral lipids in cells conditionally transformed by an activated H-ras oncogene." *Oncogene* 6(2): 289-295. Hirsch, H. A., D. Iliopoulos, et al. (2010). "A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases." *Cancer Cell*

Holvoet, P., D. H. Lee, et al. (2008). "Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome." *JAMA* 299(19): 2287-2293. Hu, Z., C. Fan, et al. (2006). "The molecular portraits of breast tumors are conserved across

Hulley, S., D. Grady, et al. (1998). "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group." *JAMA* 280(7): 605-613. Jacobs, E. J., C. C. Newton, et al. (2011). "Long-term use of cholesterol-lowering drugs and

cancer incidence in a large United States cohort." *Cancer Res* 71(5): 1763-1771.

architecture via the mevalonate pathway." *Cell* 148(1-2): 244-258.

tumour cells." *Anticancer Res* 10(3): 613-622.

cell carcinoma." *J Lipid Res* 28(10): 1177-1184.

*Opin Clin Nutr Metab Care* 9(4): 379-385.

*Natl Cancer Inst* 103(5): 364-366.

microarray platforms." *BMC Genomics* 7: 96.

17(4): 348-361.

signals through cholesterol-rich membranes." *Steroids* 72(2): 210-217.

appraisal in the management of cancer." *Pharmacol Rev* 64(1): 102-146.

cancer cell metabolism and proliferation." *Cancer Cell* 12(2): 108-113.

postmenopausal Korean women." *Cancer Causes Control* 20(7): 1055-1060.

Cancer Hospital (SEARCH) Database." *Cancer* 116(14): 3389-3398.

prostate-specific antigen levels." *J Natl Cancer Inst* 100(21): 1511-1518.


Pelucchi, C., D. Serraino, et al. (2011). "The metabolic syndrome and risk of prostate cancer in Italy." *Ann Epidemiol* 21(11): 835-841.

644 Lipoproteins – Role in Health and Diseases

control study." *Cancer*.

21(1): 61-68.

e30062.

Llaverias, G., C. Danilo, et al. (2010). "A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer." *Am J Pathol* 177(6): 3180-3191. Locke, J. A., K. M. Wasan, et al. (2008). "Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-

Manjer, J., R. Kaaks, et al. (2001). "Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo

Marcella, S. W., A. David, et al. (2011). "Statin use and fatal prostate cancer: A matched case-

Martin, R. M., L. Vatten, et al. (2009). "Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway." *Cancer Causes Control* 20(7): 1181-1192. Mello, A. P., I. T. da Silva, et al. (2011). "Electronegative low-density lipoprotein: origin and

Mogilenko, D. A., E. B. Dizhe, et al. (2009). "Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein A-I

Mondul, A. M., S. L. Clipp, et al. (2010). "Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort." *Cancer Causes Control*

Mondul, A. M., S. J. Weinstein, et al. (2011). "Serum total and HDL cholesterol and risk of

Moses, K. A., T. T. Abd, et al. (2009). "Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black americans." *J Urol* 182(5): 2219-2225. Mostaghel, E. A., K. R. Solomon, et al. (2012). "Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors." *PLoS One* 7(1):

Mulas, M. F., C. Abete, et al. (2011). "Cholesterol esters as growth regulators of lymphocytic

Nelson, P. S., N. Clegg, et al. (2002). "The program of androgen-responsive genes in neoplastic prostate epithelium." *Proc Natl Acad Sci U S A* 99(18): 11890-11895. Notarnicola, M., D. F. Altomare, et al. (2005). "Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases." *Oncology* 68(4-6): 371-374. Nygren, C., H. von Holst, et al. (1997). "Increased levels of cholesterol esters in glioma tissue

Paillasse, M. R., P. de Medina, et al. (2009). "Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion." *J* 

Parsons, J. K., J. Bergstrom, et al. (2008). "Lipids, lipoproteins and the risk of benign prostatic

Peiretti, E., S. Dessi, et al. (2007). "Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts." *Invest Ophthalmol Vis Sci* 48(8): 3450-3458.

and surrounding areas of human brain." *Br J Neurosurg* 11(3): 216-220.

hyperplasia in community-dwelling men." *BJU Int* 101(3): 313-318.

coenzyme A:Cholesterol Acyltransferase (ACAT)." *Prostate* 68(1): 20-33.

Preventive Project." *Eur J Cancer Prev* 10(1): 33-42.

impact on health and disease." *Atherosclerosis* 215(2): 257-265.

prostate cancer." *Cancer Causes Control* 22(11): 1545-1552.

leukaemia cells." *Cell Prolif* 44(4): 360-371.

*Lipid Res* 50(11): 2203-2211.

gene expression in HepG2 cells." *Biochemistry* 48(50): 11950-11960.

